PE-22-28
Description
PE-22-28 is a synthetic heptapeptide derived from the pituitary adenylate cyclase-activating polypeptide (PACAP) precursor protein, specifically residues 22-28 of the PACAP-related peptide. It is researched for its neurotrophic and neuroprotective properties. Research applications focus on cognitive function and neuronal signaling.
Research Summary
PE-22-28 is a relatively novel peptide under investigation for neurotrophic properties. Preclinical studies suggest it may promote neuronal survival and enhance synaptic plasticity through modulation of TREK-1 potassium channels. Research is in early stages, primarily limited to in vitro and rodent models.
Mechanism of Action
Proposed to inhibit TREK-1 two-pore domain potassium channels, leading to increased neuronal excitability and enhanced neurotransmitter release. This mechanism parallels the action of spadin, a natural TREK-1 inhibitor linked to neurotrophic signaling.
Known Research Compound Interactions
Based on published preclinical research literature
For laboratory research reference only. Not for human consumption. Interaction data derived from preclinical studies and receptor binding profiles. Always consult primary literature for specific research protocols.
Interaction assessments based on receptor binding affinity, signaling pathway analysis, and published preclinical data. For laboratory research use only. Not for human consumption.
Related Research
Price ComparisonPE-22-28
No pricing data available yet.
Verified vendor prices will appear here when available.
For laboratory research use only. Not for human consumption.
Verified Sources for PE-22-28
Third-party COA verified vendors that stock PE-22-28. Check our discount codes page for exclusive offers.